Charles River Laboratories to Present at March Investor Conferences
Raymond James 34th Annual Institutional Investors Conference in Orlando, Florida on Monday, March 4th, at 1:05 p.m. ET;
Cowen and Company 33rd Annual Health Care Conference in Boston, Massachusetts on Tuesday, March 5th, at 10:00 a.m. ET; and
Barclays Global Healthcare Conference in Miami, Florida on Wednesday, March 13th, at 9:30 a.m. ET.
Management will present an overview of Charles River's strategic focus and business developments.
A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website approximately three hours after each presentation and will remain available for approximately two weeks.
About Charles River
Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.
Investor Relations Contact:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
KEYWORDS: United States North America Florida Massachusetts
The article Charles River Laboratories to Present at March Investor Conferences originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.